This activity is supported by an independent education grant from ArgenX. This online education program has been designed for healthcare professionals in the United States.
Targeted therapies are expanding the treatment landscape for Pediatric Myasthenia Gravis (PMG), offering mechanism-specific disease control while reducing the cumulative burden of broad immunosuppression. Led by Dr. Abigail N. Schwaede, this session evaluates the current pediatric evidence base, regulatory approvals, and practical protocols for integrating complement inhibitors and FcRn blockers into clinical practice.
Session Highlights
- Mechanisms & Antibody-Driven Selection: Match targeted therapies to antibody status, understanding why complement inhibition is restricted to AChR-positive disease, while FcRn blockade and B-cell depletion provide mechanistically rational options for MuSK-positive patients.
- Pediatric Labelling & Evidence Gaps: Review the US pediatric indications for eculizumab and nipocalimab, noting that current pediatric approvals are grounded in adult efficacy and pediatric safety/pharmacokinetic data rather than randomized pediatric clinical trials.
- Candidacy & Sequencing: Identify when to introduce targeted therapies alongside conventional treatments, particularly for patients with refractory disease activity, unacceptable corticosteroid burden, or a need for rapid symptom control.
- Safety Protocols & Practical Barriers: Implement essential pre-treatment requirements—including meningococcal vaccination, REMS protocols, and infection plans—while navigating infusion burdens, family routines, and insurance coverage
Prefer to read? See our Key Clinical Summary Here.
Target Audience
This program is designed for healthcare professionals involved in the diagnosis, treatment, and longitudinal management of pediatric patients with pediatric myasthenia gravis (PMG). Relevant clinicians include pediatric and general neurologists, neuromuscular specialists, pediatricians, and advanced practice providers, including nurse practitioners and physician assistants.
Faculty
Dr. Abigail N. Schwaede, MD, is an Attending Physician in Neurology at Ann & Robert H. Lurie Children’s Hospital of Chicago and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. She specializes in pediatric neuromuscular disorders, with expertise in myasthenia gravis and other immune-mediated diseases, as well as Duchenne muscular dystrophy and spinal muscular atrophy. Her research focuses on electrodiagnostic tools and outcome measures in pediatric muscle diseases.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Abigail Schwaede has the following relevant financial relationships: Consultant, Advisor, Speaker: Biogen & Johnson and Johnson.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-367-H01-P
Type of Activity: Knowledge
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 15th 2027. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting October 22nd 2026, and will expire on October 15th 2027.
Estimated time to complete this activity: 15 Minutes